ABNOM
☆ AI Dermatology — Free Service
In i risultati Stiftung Warentest 2022 da Germania, a satisfaczione di i cunsumatori cù ModelDerm era solu ligeramente più bassu chè cù cunsultazioni di telemedicina pagate.
In i risultati Stiftung Warentest 2022 da Germania, a satisfaczione di i cunsumatori cù ModelDerm era solu ligeramente più bassu chè cù cunsultazioni di telemedicina pagate.
relevance score : -100.0%
ReferencesU laser Q‑switched Nd:YAG hè cunnisciutu per trattà efficacemente i nevus di Ota è cundizioni simili. Avemu realizatu un studiu per vede cumu un laser high‑fluence 1064 nm Q‑switched Nd:YAG hà travagliatu annantu à i spot monguli in zone inusuali, senza pruvucà l'irritazione cutanea. Avemu studiatu 61 pazienti cun questi spot, esaminendu un totale di 70 lesioni. A mità di e ferite hè stata trattata cù u laser, mentre chì l'altri ùn anu micca statu trattati per paragone. Avemu valutatu i risultati cù una scala è un dispositivu chjamatu Mexameter® per misurà i livelli di melanina. I pazienti sò stati seguiti per una media di 14 mesi in u gruppu di trattamentu è 18 mesi in u gruppu d’osservazione. À a fine di u studiu, avemu trovu differenze significative in i punteggi di scala è i livelli di melanina trà i gruppi trattati è non trattati, cù u gruppu trattatu cù laser chì mostrava risultati migliori. U laser high‑fluence Q‑switched Nd:YAG, senza pruvucà schiarimentu di a pelle, hè statu efficace è sicuru per trattà questi spot monguli inusuali.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
Avemu studiatu l’efficacezza è a sicurità di l’usu di un trattamentu laser specificu per ABNOM, è avemu osservatu quali fattori ponu influenzà l’efficacia. Avemu esaminatu 110 pazienti cun ABNOM chì anu ricevutu trà dui è nove trattamenti laser. Avemu trovu chì u trattamentu hà funzionatu megliu quandu è statu effettuatu più a lungo, ma i risultati sò stati menu soddisfacenti in i pazienti anziani. Funziona ancu megliu in i malati cù a pelle più chiara (tipu III) è in e zone affettate più chjuchi (menu di 10 cm²). A presenza di melasma cù ABNOM hà resu u trattamentu menu efficace. U culore o u numeru di zone affettate ùn pareva micca influenzà i risultati. Circa u 10 % di i pazienti hà sviluppatu punti più scuri dopu u trattamentu. I primi trattamenti multipli anu mostratu buoni risultati. I pazienti anziani cù a pelle più scura è i punti più scuri sò più prubabili di sviluppà macchie più scure dopu u trattamentu. Per i malati cun ABNOM è melasma, hè megliu aduprà un laser à bassa energia per evità di peggiorà u melasma.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ Trattamentu
L’agenti di imbiancatura raramente aiutanu. A differenza di u melasma, ABNOM pò esse migliuratu cù trattamentu laser è pò esse eliminatu senza recidiva. U trattamentu laser pò esse effettuatu da 10 à 20 volte per trattà ABNOM.
#QS1064 laser